

I hereby certify that this correspondence is
being deposited with the United States
Postal Service as first class mail in an
envelope addressed to:

Assistant Commissioner for Patents,
Washington, D.C. 20231

On June 13, 2002

By Victoria A. MacMillan
Victoria A. MacMillan



RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

Attorney Docket No. 0219us410

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kim Vilbour Andersen et al.

Examiner: Unassigned

Application No.: 09/997,623

Art Unit: 1646

Filed: November 29, 2001

INFORMATION DISCLOSURE
STATEMENT UNDER
37 CFR § 1.97 and § 1.98

For: PROTEIN C OR ACTIVATED
PROTEIN C-LIKE MOLECULES

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


The references cited on attached form PTO-SB/08 are being called to the attention of the Examiner, to make of record references cited in parent application USSN 09/978,917 filed October 17, 2001. Also attached is a copy of International Search Report for corresponding International Application No. PCT/DK01/00679.

Pursuant to 37 C.F.R. §1.98(d), copies of the references cited on the attached form PTO-SB/08 previously submitted in parent application USSN 09/978,917 filed October 17, 2001 are not provided herein. However, Applicants will gladly provide fresh copies of any references requested by the Examiner. It is respectfully requested that the cited information on the PTO-SB/08 form previously submitted in the parent application be expressly considered during the prosecution of the instant application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that no fee is required for submission of this statement, since it is being submitted prior to a first Office action on the merits. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joanne R. Petithory
Reg. No. 42,995

Maxygen, Inc.
Patent Department
515 Galveston Drive
Redwood City, California 94063
Telephone: (650) 298-5300
Facsimile: (650) 298-5446
Customer No. 30560

Substitute for form 1449A-B/RTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)


Complete if Known

Application Number	09/978,917 09/997,623
Filing Date	October 17, 2001 Nov. 29, 2001
First Named Inventor	Kim Vilbourn Andersen
Group Art Unit	1744 1646
Examiner Name	Unassigned
Attorney Docket Number	0219.310US 0219us410

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	4,775,624		Bang et al.	10/04/1988	
	2	4,904,584		Shaw	02/27/1990	
	3	4,959,318		Foster et al.	09/25/1990	
	4	4,968,626		Foster et al.	11/06/1990	
	5	4,992,373		Bang et al.	02/12/1991	
	6	5,041,376		Gething et al.	08/20/1991	
	7	5,073,609		Foster et al.	12/17/1991	
	8	5,151,268		Bang et al.	09/29/1992	
	9	5,196,322		Bang et al.	03/23/1993	
	10	5,225,537		Foster	07/06/1993	
	11	5,270,040		Bang et al.	12/14/1993	
	12	5,270,178		Gerlitz et al.	12/14/1993	
	13	5,302,529		Foster et al.	04/12/1994	
	14	5,358,932		Foster et al.	10/25/1994	
	15	5,453,373		Gerlitz et al.	09/26/1995	
	16	5,460,953		Gerlitz et al.	10/24/1995	
	17	5,516,650		Foster et al.	05/14/1996	
	18	5,648,254		Mulvihill et al.	07/15/1997	
	19	5,753,224		Foster et al.	05/19/1998	
	20	5,766,921		Foster et al.	06/16/1998	
	21	5,837,843		Smirnov et al.	11/17/1998	
	22	5,847,085		Esmon et al.	12/08/1998	
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)


Complete if Known

Application Number	09/978,917
Filing Date	October 17, 2001
First Named Inventor	Kim Vilb ur Andersen
Group Art Unit	1744
Examiner Name	Unassigned
Attorney Docket Number	0219.310US

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	23	EP	0 370 205	A2	Kyowa Hokko Kogyo Co., LTD.	05/30/1990		
	24	EP	0 575 054	A2	Eli Lilly and Company	12/22/1993		
	25	JP	3072877		Teijin LTD.	03/28/1991		X
	26	JP	08-092294		Teijin LTD. (ABSTRACT ONLY)	09/04/1996		X
	27	WO	89/05824	A1	Genetics Institute, Inc.	06/29/1989		
	28	WO	98/44000	A1	T.A.C. Thrombosis and Coagulation Aktiebolag	10/08/1998		
	29	WO	99/20767	A1	Regents of the University of Minnesota	04/29/1999		
	30	WO	00/26230	A1	Novo Nordisk	05/11/2000		
	31	WO	00/26354	A1	Novo Nordisk	05/11/2000		
	32	WO	00/54787	A1	The Children's Hospital of Philadelphia	09/21/2000		
	33	WO	00/66753	A2	Regents of the University of Minnesota	11/09/2000		
	34	WO	0066754	A1	Eli Lilly and Company	11/09/2000		
	35	WO	01/36463	A2	Eli Lilly and Company	05/25/2001		
	36	WO	01/57193	A2	Eli Lilly and Company	08/09/2001		
	37	WO	01/59084	A1	Eli Lilly and Company	08/16/2001		
Examiner Signature						Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/978,917
Filing Date	October 17, 2001
First Named Inventor	Kim Vilbourn Andersen
Group Art Unit	1744
Examiner Name	Unassigned
Attorney Docket Number	0219.310US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	38	COLPITTS, TRACEY L. et al., "Binding of Calcium to Individual γ -Carboxyglutamic Acid Residues of Human Protein C", <i>Biochemistry</i> , 1995, 34, 2424-2430	
	39	FRIEDRICH, UTE. et al., "Secondary Substrate-binding Exosite in the Serine Protease Domain of Activated Protein C Important for Cleavage at Arg-506 but Not at Arg-306 in Factor Va", <i>The Journal of Biological Chemistry</i> , 2001, Vol. 276, No. 25:23105-23108	
	40	FRIEDRICH, UTE et al., "Structural and Energetic Characteristics of the Heparin-binding Site in Antithrombotic Protein C", <i>The Journal of Biological Chemistry</i> , 2001, Vol. 276, No. 26:24122-24128	
	41	GALE, ANDREW J. et al., "The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites", <i>Blood</i> , 2000, Vol. 96, No. 2:585-593	
	42	GALE, ANDREW J. et al., "Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va" <i>Protein Science</i> , (1997), 6:132-140	
	43	GENG, JIE-PING et al., "Functional Consequences of Mutations in Amino Acid Residues that Stabilize Calcium Binding to the First Epidermal Growth Factor Homology Domain of Human Protein C", <i>Thrombosis and Haemostasis</i> , (1990) 76:720-728	
	44	GERLITZ, BRUCE et al., "Mutation of Protease Domain Residues Lys37-39 in Human Protein C Inhibits Activation by the Thrombomodulin-Thrombin Complex without Affecting Activation by Free Thrombin", <i>The Journal of Biological Chemistry</i> , 1996, Vol. 271, No. 37:22285-22288	
	45	HALLAM, PAULA J. et al., "A novel missense mutation (Thr176→Ile) at the putative hinge of the neo N-terminus of activated protein C", <i>Hum Genet</i> , (1995) 95:447-450	
	46	HOLLY, RICK D. et al., "Resistance to inhibition by α -1-Anti-Trypsin and Species Specificity of a Chimeric Human/Bovine Protein C", <i>Biochemistry</i> , (1994) 33:1876-1880	
	47	JHINGAN, ASHISH et al., "The Activities of Recombinant γ -Carboxyglutamic-Acid-Deficient Mutants of Activated Human Protein C toward Human Coagulation Factor Va and Factor VIII in Purified Systems and in Plasma", <i>Biochemistry</i> , (1994) 33:1869-1875	
	48	MCDONALD, JOHN F. et al., "Comparison of Naturally Occurring Vitamin K-Dependent Proteins: Correlation of Amino Acid Sequences and Membrane Binding Properties Suggests a Membrane Contact Site", <i>Biochemistry</i> , (1997) 36:5120-5127	
	49	MESTERS, ROLF M. et al., "A Novel Exosite in the Light Chain of Human Activated Protein C Essential for Interaction with Blood Coagulation Factor Va", <i>Biochemistry</i> , (1993) 32:12656-12663	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/978,917
	Filing Date	October 17, 2001
	First Named Inventor	Kim Vilb ur Andersen
	Group Art Unit	1744
	Examiner Name	Unassigned
	Attorney Docket Number	0219.310US

50	MESTERS, ROLF M. et al., "Identification of a Sequence of Human Activated Protein C (Residues 390-404) Essential for Its Anticoagulant Activity", <i>The Journal of Biological Chemistry</i> , 1991, Vol.266, No. 36:24514-24519	
51	NISHIOKA, JUNJI et al., "The Gla26 Residue of Protein C is Required for the Binding of Protein C to Thrombomodulin and Endothelial Cell Protein C Receptor, but not to Protein S and Factor Va", <i>Thrombosis and Haemostasis</i> , (1996) 75:275-282	
52	ÖHLIN, ANN-KRISTIN et al., "Proteolytic Formation and Properties of a Fragment of Protein C Containing the γ -Carboxyglutamic Acid Rich Domain and the EGF-like Region", <i>Biochemistry</i> , (1990) 29:644-651	
53	REZAIIE, ALIREZA, R. "Role of Residue 99 at the S2 Subsite of Factor Xa and Activated Protein C in Enzyme Specificity", <i>The Journal of Biological Chemistry</i> , 1996, Vol. 271, No. 39:23807-23814	
54	REZAIIE, ALIREZA, R. "Calcium inhibition of the activation of protein C by thrombin Role of the P3 and P3' residues", <i>Eur. J. Biochem.</i> , (1994) 223:575-579	
55	REZAIIE, ALIREZA, R. "Vitronectin Functions as a Cofactor for Rapid Inhibition of Activated Protein C by Plasminogen Activator Inhibitor-1", <i>The Journal of Biological Chemistry</i> , May 11, 2001, Vol. 276, No. 19:15567-15570	
56	REZAIIE, ALIREZA, R. et al., "Conversion of Glutamic Acid 192 to Glutamine in Activated Protein C Changes the Substrate Specificity and Increases Reactivity toward Macromolecular Inhibitors", <i>The Journal of Biological Chemistry</i> , 1993, Vol. 268, No. 27:19943-19948	
57	RINTELEN, CLAUDIA et al., "Anticoagulant Dysfunction of Human Arg352Trp-Activated Protein C Caused by Defective Factor Va Inactivation", <i>Thrombosis and Haemostasis</i> , (2001) 85:274-279	
58	SHEN, LEI et al., "Enhancing the Activity of Protein C by Mutagenesis To Improve the Membrane-Binding Site: Studies Related to Proline-10", <i>Biochemistry</i> , 1997, Vol. 36, No. 51:16025-16031	
59	SHEN, LEI et al., "Enhancement of Human Protein C Function by Site-directed Mutagenesis of the γ -Carboxyglutamic Acid Domain", <i>The Journal of Biological Chemistry</i> , 1998, Vol. 273, No. 47:31086-31091	
60	SHEN, LEI et al., "Interspecies Loop Grafting in the Protease Domain of Human Protein C Yielding Enhanced Catalytic and Anticoagulant Activity", <i>Thrombosis and Haemostasis</i> , (1999) 82:1078-1087	
61	SHEN, LEI et al., "Tracking Structural Features Leading to Resistance of Activated Protein C to α 1-antitrypsin", <i>Biochemistry</i> , (2000) 39:2853-2860	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	09/978,917
	Filing Date	October 17, 2001
	First Named Inventor	Kim Vilbourn Andersen
	Group Art Unit	1744
	Examiner Name	Unassigned
	Attorney Docket Number	0219.310US

62	THARIATH, ABRAHAM et al., "Highly conserved residue arginine-15 is required for the Ca ²⁺ -dependent properties of the γ -carboxyglutamic acid domain of human anticoagulation Protein C and activated Protein C", <i>Biochem. J.</i> , (1997) 322:309-315	
63	ZHANG, LI et al., "Role of Individual γ -Carboxyglutamic Acid Residues of Activated Human Protein C in Defining its In Vitro Anticoagulant Activity", <i>Blood</i> , 1992, Vol. 80, No. 4:942-952	
64	ZHANG, LI et al., "The Binding Energy of Human Coagulation Protein C to Acidic Phospholipid Vesicles Contains a Major Contribution from Leucine 5 in the γ -Carboxyglutamic Acid Domain", <i>The Journal of Biological Chemistry</i> , 1994, Vol. 269, No.5:3590-3595	
65	ZHANG, LI et al., "Role of the Hexapeptide Disulfide Loop Present in the γ -Carboxyglutamic Acid Domain of Human Protein C in Its Activation Properties and in the in Vitro Anticoagulant Activity of Activated Protein C", <i>Biochemistry</i> , (1991) 30:6696-6704	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.